

# UNCLASSIFIED

|                                                                                                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                             |
| AD NUMBER                                                                                                                                                                                                                   |
| ADB257200                                                                                                                                                                                                                   |
| NEW LIMITATION CHANGE                                                                                                                                                                                                       |
| TO<br>Approved for public release, distribution unlimited                                                                                                                                                                   |
| FROM<br>Distribution authorized to U.S. Gov't. agencies only; Proprietary Info; Jul 99. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, MD 21702-5012. |
| AUTHORITY                                                                                                                                                                                                                   |
| USAMRMC ltr, dtd 10 Jun 2003                                                                                                                                                                                                |

THIS PAGE IS UNCLASSIFIED

AD\_\_\_\_\_

GRANT NUMBER DAMD17-98-1-8216

TITLE: Determination of Catechol Estrogen Adducts by High-Performance Liquid Chromatography: Establishing Biomarkers for the Early Detection of Breast Cancer

PRINCIPAL INVESTIGATOR: Douglas E. Stack, Ph.D.

CONTRACTING ORGANIZATION: University of Nebraska at Omaha  
Omaha, Nebraska 68182-0210

REPORT DATE: July 1999

TYPE OF REPORT: Annual

PREPARED FOR:

U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

Distribution Statement: Distribution authorized to U.S. Government agencies only (proprietary information, Jul 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTION

20000822 064

## NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

### LIMITED RIGHTS LEGEND

Award Number: DAMD17-98-1-8216

Organization: University of Nebraska at Omaha

Location of Limited Rights Data (Pages):

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

---

---

---

---

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                             |                                                            |                                                                  |  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------------|--|
| 1. AGENCY USE ONLY (Leave blank)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                             | 2. REPORT DATE<br>July 1999                                | 3. REPORT TYPE AND DATES COVERED<br>Annual (1 Jun 98 - 1 Jun 99) |  |
| 4. TITLE AND SUBTITLE<br>Determination of Catechol Estrogen Adducts by High-Performance Liquid Chromatography: Establishing Biomarkers for the Early Detection of Breast Cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                             |                                                            | 5. FUNDING NUMBERS<br>DAMD17-98-1-8216                           |  |
| 6. AUTHOR(S)<br>Douglas E. Stack, Ph.D.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                             |                                                            |                                                                  |  |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br>University of Nebraska at Omaha<br>Omaha, Nebraska 68182-0210                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                             |                                                            | 8. PERFORMING ORGANIZATION<br>REPORT NUMBER                      |  |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                             |                                                            | 10. SPONSORING / MONITORING<br>AGENCY REPORT NUMBER              |  |
| 11. SUPPLEMENTARY NOTES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                             |                                                            |                                                                  |  |
| 12a. DISTRIBUTION / AVAILABILITY STATEMENT<br><br>Distribution authorized to U.S. Government agencies only (proprietary information, Jul 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                             |                                                            | 12b. DISTRIBUTION CODE                                           |  |
| 13. ABSTRACT (Maximum 200 words)<br><br>The metabolism of estrogen produces reactive electrophiles, catechol estrogen quinones (CE-Q). CE-Q have been shown to be genotoxic, reacting with DNA to produce CE-DNA adducts. In order to determine the correlation between formation of CE-Q and breast cancer, an analytical protocol that can measure CE-DNA adducts at ultra-low, endogenous levels in breast tissue is being developed. The synthesis of novel fluorescent probes specific to the catechol moiety was the focus of this year's work. These fluorescent probes will allow HPLC analysis of CE metabolites and CE-DNA adducts at the femtomolar level. Starting from anthracene, dichloro-di-(9-anthryl)methane was synthesized in three steps. The dibromo analog is also under production. In addition, probes base on fluorene have been generated so that derivation of catechol structures leads to a spiro ring system. The production of a spiro ring system was also explored using the commercially available dichlorodiphenylsilane. The synthesis of gram quantities of 4-hydroxyestrone and 4-hydroxyestradiol was also accomplished in year 1. The ultimate goal of this research is the development of a biomarker for the early detection of breast cancer. |                                                             |                                                            |                                                                  |  |
| 14. SUBJECT TERMS<br>Breast Cancer Biomarkers, Breast Cancer Etiology, Fluorescence Markers, HPLC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                             |                                                            | 15. NUMBER OF PAGES<br>12                                        |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                             |                                                            | 16. PRICE CODE                                                   |  |
| 17. SECURITY CLASSIFICATION<br>OF REPORT<br>Unclassified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 18. SECURITY CLASSIFICATION<br>OF THIS PAGE<br>Unclassified | 19. SECURITY CLASSIFICATION<br>OF ABSTRACT<br>Unclassified | 20. LIMITATION OF ABSTRACT<br>Limited                            |  |

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

\_\_\_\_ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

✓ \_\_\_\_ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

\_\_\_\_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

\_\_\_\_ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
PI - Signature

Date

## TABLE OF CONTENTS

|                                   |   |
|-----------------------------------|---|
| Front Cover.....                  |   |
| SF-298.....                       | 2 |
| Foreword.....                     | 3 |
| Table of Contents.....            | 4 |
| Introduction.....                 | 5 |
| Body.....                         | 5 |
| Key Research Accomplishments..... | 7 |
| Reportable Outcomes.....          | 7 |
| Conclusions.....                  | 7 |
| References.....                   | 8 |
| Appendices.....                   | 9 |

**INTRODUCTION:**

The metabolism of estrogen to procarcinogenic catechols has been hypothesized as an initiation step in the development of breast cancer [1-4]. Specifically, the over expression of 4-hydroxylase activity has been observed in organs prone to estrogen-induced tumors [5-8]. The role of 4-hydroxyestradiol (4-OHE<sub>2</sub>) and 4-hydroxyestrone (4-OHE<sub>1</sub>) metabolites with the increase occurrence of estrogen-induced tumors is still not clear. Hypothesis regarding redox-cycling [9-13] and oxidation to electrophilic quinones have been examined [3,4]. Since oxidation of catechol estrogens (CE) to catechol estrogen quinones (CE-Q) has been shown to lead to CE-DNA adducts [4], we seek to develop an analytical technique that can measure these adducts at biologically meaningful, endogenous levels. The purpose of developing this assay is to examine whether CE-DNA adducts are present in breast cancer tissue. This would be a first step in understanding the etiology of breast cancer as it relates to estrogen metabolism; specifically, the role of 4-hydroxylase activity in the increase occurrence of estrogen-induced cancers. The scope of this method development involves the production of fluorescent probes, specific for the catechol moiety, so that ultra, low-level detection of these adducts can be accomplished. With the proper development of fluorescent probes, this assay would not only be very sensitive, but selective towards the oxidatively liable CE-DNA adducts.

**BODY:**

Task 1 in our statement of work, "Task 1. Develop an extraction procedure for the isolation of CE-adducts, CE and MPEM from rat mammary tissue. (Months 1-14)." was not an initial focus in year 1 of this grant. Instead, we decided to concentrate on Task 2, "Task 2. Develop an HPLC analytical procedure, via pre-column fluorescence derivatization, for the femtomolar detection of CE-adducts, CE and MPEM in human breast tissue. (Months 15-30)." This was done since Task 1 relied heavily on the acquisition of a new high performance liquid chromatograph (HPLC) for which matching funds were not available for the summer research period. Since this work is being conducted in an undergraduate institution, the summer research period is when the maximum work effort (via undergraduate research assistants) can be devoted to the tasks outlined in the statement of work. The development of different fluorescent probes, the initial focus of Task 2, does not rely on state-of-the-art HPLC equipment. Since the purchase of a new HPLC system has now been implemented, Task 1 will become the focus of our work sometime during the course of year 2. Thus, the research described below will summarize our synthetic efforts in developing several fluorescent probe candidates for accomplishing Task 2.

Initially, we sought to use a fluorescent probe that was commercially available, *m*-dansylaminophenylboronic acid (DABA). However the use of DABA was found not to be acceptable for reverse phase HPLC conditions. The reason lies in the equilibrium of binding to phenolic hydroxy groups. The equilibrium in Figure 1 can be 'push' to the side of the derivatized product if water is removed during the course of the reaction. Under conditions of reverse phase HPLC, the DABA probe is hydrolyzed back to the boronic acid leaving the catechol underviatized and non-fluorescent. Thus, a novel fluorescent probe capable of irreversible binding in the presence of water had to be synthesized.

The production of a new fluorescent probe specific for the catechol moiety requires the consideration of several issues. Quantum yields for fluorescent molecules are highest in rigid systems with minimal conformational flexibility near the fluorescent emitting portion of the molecule [14]. This is why the DABA probe was sought as a replacement to earlier fluorescent markers used by us on CE and CE-DNA adducts [15]. The binding of both phenol hydroxy groups onto a single atom generates a new ring system with reduced conformational flexibility when compared to the binding of two separate fluorescent probes (Figure 2). Thus, the design of our new probe was conducted with several features in mind. First, a highly fluorescent

fluorophore was selected to maximize sensitivity. Second, the fluorophore should be attached to an atom bearing two electrophilic leaving groups so that reaction with both nucleophilic phenol hydroxy groups could take place leading to the formation of a five membered ring. Third, the atom possessing the two electrophilic leaving groups could not be prochiral because formation of a new chiral center would produce a mixture of diastereomeric products (since the estrogen ring system is chiral), complicating separation and quantitation of CE-DNA adducts. Fourth, the reaction with phenols should take place in near quantitative fashion, under mild conditions, in solvents conducive to reverse phase HPLC. We have explored several structures that can satisfy these requirements.

Scheme 1 shows the synthetic steps used to produce the first fluorescent probe we believe will meet requirements stated above. Dibromo-di-(9-anthryl)methane should produce a highly reactive probe with intense fluorescent emission. The synthesis of this molecule started from anthracene which was brominated by *N*-bromosuccinimide (NBS) in anhydrous dimethylformamide (DMF) to furnish 9-bromoanthracene (**1**) in good yield. In situ lithation of (**1**) in the presence of *N,N,N,N*-tetraethylurea produces the symmetrical ketone (**2**). The chlorination of (**2**) with  $\text{PCl}_5$  produced dichloro-di-(9-anthryl)methane, (**3**), in 70% yield. The reaction of (**3**) with the catechol ring system will be conducted when the fluorescence detector and corresponding HPLC arrives later this summer. Since the dichloro compound (**3**) may not possess sufficient reactivity to couple with catechols, the production of the dibromo analog has been undertaken. Reduction of (**3**) with mossy Zn in NaOH generated the hydrocarbon (**4**). We will brominate (**4**) at the benzylic position with NBS to produce (**5**) early in year 2. Since anthracene is one of the more sensitive fluorophores known, we expect these probes will allow detection of catechol ring systems at the femtomolar level.

The synthesis of probe (**5**) was first attempted by direct lithation of anthracene by *n*-BuLi. This route was to afford a preformed organolithium compound which could react with the commercially available 9-anthracenecarboxylic acid. However, the reaction of *n*-BuLi with anthracene produced the addition product, 9-butyl-9,10-dihydroanthracene. Even lithation of (**1**) with *n*-BuLi followed by reaction with 9-anthracenecarboxylic acid afforded no ketone product. Thus the route depicted in Scheme 1 was chosen as an alternative.

Since fluorescence is affected by conformational rigidity, a fluorescent probe which results in the formation of a spiro adduct is being pursued. Scheme 2 shows our reaction of fluorene with NBS to produce 9,9-dibromofluorene. We will react this dibromomide with catechols to produce the derived structure (**6**). The ridged spiro junction could increase the quantum yield of this fluorophore.

The reaction of dichlorodiphenylsilane in the presence of catechol was undertaken to afford the spiro product (**7**). The fluorescence properties, as well as stability towards hydrolysis, will be investigated. Dichlorodiphenylsilane was chosen since it was commercially available, and it would have the added advantage of not possessing any significant fluorescent properties. An effective fluorescence derivation strategy involves formation of a new fluorophore from non-fluorescent starting materials. This reduces background interference from the fluorescent probe which is usually applied in excess during the derivation process.

In addition to the synthetic work outlined above, considerable effort was expended to producing 4-OHE<sub>1</sub> and 4-OHE<sub>2</sub> from estrone and estradiol, respectively. While the synthetic procedures for these syntheses are known, they involve several steps and consume considerable personnel time to generate gram quantities of these catechols. These catechols will be needed for the investigation of fluorescent probes suitable for HPLC analysis, as well as, production of the CE-DNA adducts that will serve as the eventual biomarkers.

### **KEY RESEARCH ACCOMPLISHMENTS:**

- Synthesis of gram quantities of 4-OHE<sub>1</sub> and 4-OH<sub>2</sub> for production of CE-DNA adducts.
- Establishment of the inappropriate nature of DABA as a fluorescence probe for catechols.
- Synthesis of dichloro-di-(9-anthryl)methane as a potential fluorescence probe for catechol ring systems.
- Synthesis of di-(9-anthryl)methane as a precursor to dibromo-di-(9-anthryl)methane, a more reactive analog to dichloro-di-(9-anthryl)methane.
- Coupling of dichlorodiphenylsilane to catechol to form the siloxy adduct which will be examined for fluorescent properties.

### **REPORTABLE OUTCOMES:**

- 1) A local grant entitled, "Establishment of Biomarkers for the Early Detection of Breast Cancer", was submitted and obtain from The University Council on Research, University of Nebraska at Omaha. The amount was \$8,300 and was used to match equipment funds needed for a new HPLC purchase.
- 2) Two Undergraduates, Clark Diffendaffer and Matthew Nammany, were employed full time during the summer of 1998. Their training in synthetic processes and analytical procedures not only provided for summer employment, but also furthered their academic goals relating to careers in health care.

### **CONCLUSIONS:**

We have completed most the synthetic requirements, which were many, for this project. Now that most of the synthetic perquisites have been completed, we will be able to start development of the analytical methodology. The time spent producing several fluorescent probes will pay dividends when various analytical approaches are implemented. While our primary goal will be the use of HPLC coupled to fluorescence detection, followed by verification of adducts via mass spectrometry, the production of several fluorescent probes will allow other analytical procedures to be examined. For instance, collaboration with Ryszard Janowiak at Iowa State University has been established so that the derivatized catechol products can be examined by fluorescence line narrowing spectroscopy (FLNS). FLNS was used in our prior work [7] with earlier fluorescent probes. The flexibility of these probes made the identification of CE metabolites from CE-DNA adducts difficult. By producing new fluorescent probes which are more conformationally ridged, the FLNS spectra of these derived adducts could be used to unequivocally verify structure. Dr. Jankowaik is developing the ability of obtain FLNS spectra directly from capillary electrophoresis separations. Thus, our probes could be instrumental in the development of a separation protocol that could quantitate, and identify CE metabolites and CE-DNA adducts, simultaneously.

The development of an analytical assay that can measure CE-DNA adducts at endogenous levels is scientifically and medically important for several reasons. First, while the link between increased estrogen exposure and increased rates of breast cancer have been established, the mechanism relating estrogen to cancer is still unknown. While the hormonal properties, i.e. proliferation of cell growth, associated with estrogen certainly is an important area of research, the role of estrogen metabolites as initiators of DNA damage needs to be clarified. In order to establish a link between metabolic production of CE-Q and breast cancer, the CE-DNA adducts produced when these electrophiles bind to DNA must be measured in human tissues. This requires an ultra sensitive analytical process since these CE-DNA adducts


will no doubt be produced at very low levels. If the detection of CE-DNA adducts in human tissues, and later in fluids (e.g. plasma and urine), establishes a link between breast cancer and the production of these adducts, a new biomarker for the early detection of breast cancer would be at hand. In addition to an effective biomarker, the ability to measure these adducts in different models could lead to strategies aimed at prevention of estrogen-induced cancers.

## **REFERENCES:**


- 1) Liehr, J.G. (1990) Genotoxic effects of estrogens. *Mutat. Res.*, 238, 269-276.
- 2) Dwivedy, I., Devanesan, P.D., Cremonesi, P., Rogan, E.G., and Cavalieri, E.L. (1992) Synthesis and characterization of estrogen 2,3- and 3,4-quinones. Comparison of the DNA adducts formed by the quinones versus horseradish peroxidase-activated catechol estrogens. *Chem. Res. Toxicol.*, 5, 828-833.
- 3) Stack, D., Byun, J., Gross, M.L., Rogan, E.G., and Cavalieri, E.L. (1996) Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. *Chem. Res. Toxicol.*, 9, 851-859.
- 4) Cavalieri, E., Stack D., Devanesan, P., Todorovic, R., Dwivedy, I., Higginbotham, S., Johansson, S., Patil, K., Gross, M., Gooden, J., Ramanathan, R., Cerny, R. and Rogan, E. (1997) Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators. *Proc. Natl. Acad. Sci. USA*, 94, 10937.
- 5) Spink, D.C., Eugster, H.P., Lincoln II, D.W., Schuetz, J.D., Schuetz, E.G., Johnson, J.A., Kaminsky, L.S., and Gierthy, J.F. (1992) 17 Beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: A comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. *Arch. Biochem. Biophys.*, 293, 342-348.
- 6) Liehr, J.G., Ricci, M.J., Jefcoate, C.R., Hannigan, E.V., Hokanson, J.A., and Zhu, B.T. (1995) 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: Implications for the mechanism of uterine tumorigenesis. *Proc. Natl. Acad. Sci. U.S.A.* 92, 9220-9224.
- 7) Liehr, J.G., and Ricci, M.J. (1996) 4-Hydroxylation of estrogens as marker of human mammary tumors. *Proc. Natl. Acad. Sci. U.S.A.*, 93, 3294-3296.
- 8) Castagnetta, L.A., Granata, O.M., Arcuri, F.P., Polito, L.M., Rosati, F. and Cartoni, G.P. (1992) Gas chromatography/mass spectrometry of catechol estrogens. *Steroids*, 57, 437-443.
- 9) Liehr JG (1997) Hormone-associated cancer: mechanistic similarities between human breast cancer and estrogen-induced kidney carcinogenesis in hamsters. *Environ Health Perspect* 105 Suppl 3, 565-569.
- 10) Liehr JG (1997) Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. *Eur J Cancer Prev* 6, 3-10.
- 11) Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. *Annu Rev Pharmacol Toxicol* 36, 203-232.
- 12) Han X, Liehr JG (1994) 8-Hydroxylation of guanine bases in kidney and liver DNA of hamsters treated with estradiol: role of free radicals in estrogen-induced carcinogenesis. *Cancer Res* 54, 5515-5517.
- 13) Roy D, Floyd RA, Liehr JG (1991) Elevated 8-hydroxydeoxyguanosine levels in DNA of diethylstilbestrol-treated Syrian hamsters: covalent DNA damage by free radicals generated by redox cycling of diethylstilbestrol. *Cancer Res* 51, 3882-3885.

- 14) Wehry, E. L. In *Practical Fluorescence*, 2<sup>nd</sup> ed.; Guilbault G. G., Ed.; Marcel Dekker, Inc.: New York, 1990; pp 117-120.
- 15) Janowiak, R., Zamzow, D., Stack, D.E., Todorovic, R., Cavalieri, E.L. and Small, G.J. (1998) Spectral characterization of fluorescently labeled catechol estrogen-3,4-quinone derived -N7Gua adducts and their identification in rat mammary gland tissue. *Chem. Res. Toxicol*, 11, 1339.


## APPENDIES:




**Figure 1. Unfavorable equilibrium of DABA binding with catechols.**




**Figure 2. Structural features of a successful fluorescent probe.**



**Figure 3. Fluorescence probe based on fluorcene.**



**Figure 4. Spiro adduct of catechol and dichlorodiphenylsilane.**



Scheme 1. Synthesis of dihalo-di-(9-anthryl)methane fluorescent probes.



DEPARTMENT OF THE ARMY  
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND  
504 SCOTT STREET  
FORT DETRICK, MD 21702-5012

REPLY TO  
ATTENTION OF

MCMR-RMI-S (70-1y)

10 Jun 03

MEMORANDUM FOR Administrator, Defense Technical Information  
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,  
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.
2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl

PHYLLIS M. RINEHART  
Deputy Chief of Staff for  
Information Management

ADB270849  
ADB263653  
ADB282255  
ADB262232  
ADB277418  
ADB285664  
ADB281628  
ADB284965  
ADB265796  
ADB282152  
ADB285670  
ADB257200  
ADB266081  
ADB285703  
ADB285699  
ADB285481  
ADB285668  
ADB283633